Peptides - Metabolic
Tirzepatide
Dual GLP-1/GIP agonist for weight management and metabolic health
Dosage
2.5-15mg weekly
Results
4-12 weeks
Frequency
Weekly
Cost
$300-500/month
Estimated monthly
$300-500
About Tirzepatide
Tirzepatide is a dual GLP-1/GIP receptor agonist approved by the FDA under the brand names Mounjaro and Zepbound. Clinical trials have demonstrated impressive weight loss results and improved glycemic control. It works by enhancing insulin secretion, reducing appetite, and slowing gastric emptying.
Administration
Method
Subcutaneous injection
Timing
AM
Food
Any time
Key Benefits
- Substantial weight loss
- Improved blood sugar control
- Reduced appetite
- Cardiovascular benefits
- FDA-approved
Stacks Well With
Important Considerations
- • MEN2
- • Thyroid cancer history
- • Pancreatitis
- • Pregnancy
Additional Notes
- • FDA-approved as Mounjaro/Zepbound
- • Titrate up gradually
Research & Studies
Tirzepatide: SURMOUNT-1 Weight Loss Trial
2022·Clinical Trial
Tirzepatide: Dual GIP/GLP-1 Receptor Agonist
2021·Clinical Trial
Research provided for educational purposes. Always consult a healthcare provider.